Rare diseases and the orphan drug shortage: : How Mark Cuban’s Cost-Plus Model Is Forcing a Reckoning

"All hat, no cattle" is an apt description of Michigan's new Rare Disease Advisory Council. Sometimes, bills become law just because people desperately need hope, even though the proposed law has no hope of making a real difference.
https://mihealthfreedom.org/community/senate-hpol/telehealth-contacts-rare-disease-council-med-aide-permit-repeal-emergency-refills-health-insurance-exchange/#post-494

Wins are scarce in the rare disease realm, so this week's Stat News headline touting Mark Cuban's initiative caught my eye.
https://www.statnews.com/2026/10/21/mark-cuban-cost-plus-drugs-rare-disease-medicines/

Although the article is paywalled, the following 17-point longform deep backgrounder is accessible with email entry, and may be even better. Everything you ever wanted to know about rare diseases in the marketplace, where actual productivity matters!

Drug Patent Watch provides business intelligence on Biologic and Small Molecule Drugs. Clipped for length.

https://www.drugpatentwatch.com/blog/mark-cuban-unexpected-leader-in-orphan-drug-development-reform/

Orphan Drug Reform: How Mark Cuban’s Cost-Plus Model Is Forcing a Reckoning

April 18, 2026

1. Why This Matters Now

Rare disease drugs now account for 52% of all new molecular entities (NMEs) approved by FDA’s Center for Drug Evaluation and Research in 2024, up from 39% in 2017. That shift is not accidental. The Orphan Drug Act of 1983 built a regulatory architecture that makes the rare disease space financially superior to standard pharmaceutical development, producing gross profit margins above 80% versus the broader industry average of roughly 16%.

That profitability has attracted scrutiny from every direction simultaneously: Medicare negotiation provisions in the Inflation Reduction Act, bipartisan legislative pressure through the ORPHAN Cures Act, a federal appeals court decision that upended 40 years of FDA interpretation of exclusivity scope, and a publicly traded pharmacy-manufacturing hybrid built by a billionaire whose explicit stated goal is to ‘f— up the drug industry in every way possible.’

The convergence of these forces creates both risk and opportunity that IP teams and investors cannot model accurately without understanding the mechanics of each in detail. This pillar page provides that detail.

2. Mark Cuban and the Origin of Cost Plus Drugs

Cuban’s History of Attacking Market Opacity
Before the Mark Cuban Cost Plus Drug Company existed, Cuban’s track record of challenging information asymmetry was already documented. He funded Sharesleuth, an investigative outlet targeting financial fraud. He endowed the Electronic Frontier Foundation’s ‘Mark Cuban Chair to Eliminate Dumbass Patents,’ a direct shot at non-practicing entities that exploit IP without producing anything. Both efforts share a structural logic: identify a market where opacity or monopoly creates value extraction without corresponding value creation, then attack the opacity directly.

His entry into healthcare follows the same logic. After watching Martin Shkreli’s 5,000% price hike on Daraprim (pyrimethamine) and seeing generic medication shortages proliferate across hospital formularies, Cuban concluded the pharmaceutical supply chain had no functioning price signal. His public characterization of the problem was precise: ‘You simply cannot find the price or cost of drugs.’ Not ‘hard to find.’ Cannot find.

That observation, combined with a cold email from Dr. Alex Oshmyansky in 2018, produced the company.

The Oshmyansky Partnership and the PBC Structure
Oshmyansky had been operating since 2015 under the name ‘Osh’s Affordable Pharmaceuticals,’ focused specifically on generic drugs for rare diseases whose prices had been hiked dramatically. He had direct knowledge of the manufacturing and distribution mechanics and a specific thesis: that removing intermediary layers from the generic supply chain could reduce costs by 80 to 90 percent for many molecules.

Cuban invested by 2019 and agreed to rename the venture the Mark Cuban Cost Plus Drug Company, the only instance he has put his name on a company he backed rather than founded. That decision is not incidental. The brand is an explicit commercial and political statement.

The legal structure matters as much as the brand. MCCPDC is incorporated as a Public Benefit Corporation (PBC), a legal form that gives boards statutory protection from shareholder lawsuits when they pursue social objectives at the expense of short-term profit maximization. This is not window dressing. It means Cuban can undercut market prices on strategically important drugs, absorb operating losses in specific categories, or prioritize shortage drugs with thin margins, without triggering fiduciary liability. The social mission is written into the corporate DNA.

Key Takeaways: Section 2

Cuban’s MCCPDC is a logical extension of his documented pattern of attacking information asymmetry and IP system abuse, not a philanthropic detour.
The PBC corporate structure gives management legal cover to pursue mission-driven decisions that would otherwise expose a standard C-corp to shareholder litigation.
Oshmyansky’s original focus on rare disease generics remains embedded in the company’s manufacturing strategy, even as the pharmacy catalog has grown past 2,200 drugs.

3. The Orphan Drug Act: Mechanics, Incentives, and IP Architecture

Pre-1983 Baseline
Before the Orphan Drug Act passed in January 1983, the FDA had approved roughly 10 treatments for conditions affecting fewer than 200,000 U.S. patients across the entire preceding decade. The economic rationale was clear: a drug serving 50,000 patients cannot generate revenue sufficient to recover a $300 million development investment at any price the market will bear, and the U.S. patent system provides no special accommodation for small-market products.

Patient advocates, led by figures including Abbey Meyers and Muriel Seligman through the National Organization for Rare Disorders (NORD), successfully argued that market failure was not a justification for abandoning patients to untreated disease. Congress agreed and passed the ODA with a suite of financial incentives designed to change the calculus.

The ODA Incentive Stack: Full Mechanics
The ODA does not operate through a single lever. It stacks multiple incentives, and understanding how they interact is essential for accurate IP valuation of rare disease assets.

Tax Credits: The original act offered a 50% tax credit on qualified clinical testing expenses for designated orphan drugs. The Tax Cuts and Jobs Act of 2017 cut this to 25%, a reduction the industry protested vigorously and which measurably affected development economics for smaller sponsors.

Grant Funding: The FDA’s Office of Orphan Product Development (OOPD) administers grants directly covering clinical research costs for orphan-designated products. These grants reduce the capital at risk for sponsors before proof-of-concept data exists.

FDA User Fee Waivers: Prescription Drug User Fee Act (PDUFA) fees, which can reach several million dollars per application, are waived entirely for orphan drug applications. For a small biotech with one asset, this waiver can represent 20 to 30% of the cash runway available for a regulatory submission.

Seven-Year Market Exclusivity (Orphan Drug Exclusivity, ODE): This is the dominant economic lever. The FDA cannot approve a ‘same drug for the same disease or condition’ from a different manufacturer for seven years after approval, regardless of patent status. ODE runs independently of patent protection. A drug can be off-patent and still hold ODE. Pediatric studies can extend ODE by a further six months under the Pediatric Research Equity Act if the sponsor completes a qualified pediatric study.

Priority Review and FDA Development Assistance: OOPD provides direct protocol assistance, parallel scientific reviews, and expedited FDA feedback throughout development, compressing timeline and reducing uncertainty costs.

The combination of these incentives converts a structurally unprofitable market into a viable, and in many cases highly profitable, one. The problem regulators now confront is that the incentives were calibrated for a pre-genomics era where rare disease patients numbered in the tens of thousands and drug development was almost entirely small-molecule chemistry. Neither assumption holds today.

Regulatory Exclusivity vs. Patent Protection: Why Both Matter
IP analysis in orphan drug contexts requires tracking at least four overlapping protection periods simultaneously. Base patent protection runs 20 years from the filing date, but average effective market exclusivity at launch is 12 to 14 years after accounting for development and review timelines. Patent Term Extensions (PTEs) under the Hatch-Waxman Act can restore up to five years of patent term lost during FDA review. New Chemical Entity (NCE) exclusivity under the Federal Food, Drug, and Cosmetic Act provides five years of data exclusivity for first-in-class small molecules, during which no generic Abbreviated New Drug Application (ANDA) can even be filed. New clinical investigation exclusivity provides three years for new uses of previously approved drugs where the sponsor conducts new studies. ODE layers on top of or alongside all of these.

For a well-structured orphan drug asset, total protected market life from first approval can exceed 14 years in some scenarios. For a poorly structured or legally challenged asset, effective exclusivity can collapse to the seven-year ODE floor or less.

Key Takeaways: Section 3

The ODA incentive stack includes five distinct components whose aggregate financial value varies significantly by asset type, sponsor size, and indication.
The 2017 tax credit reduction from 50% to 25% created the first major chill in orphan drug investment in the act’s history.
ODE and patent protection are legally independent. An orphan drug can hold ODE after all relevant patents expire, making ODE the last line of market defense for many assets.

4. Orphan Drug Exclusivity as a Core Asset: IP Valuation Framework
Valuing ODE in a DCF Model
For IP teams and portfolio managers, ODE has a quantifiable economic value that must be modeled separately from the patent estate. The core inputs are: peak annual revenue at current list price, the revenue discount rate once a competitor enters (historically 60 to 80% decline in year one post-ODE expiry for diseases with real generic competition), the probability of ODE being successfully defended through litigation or regulatory action, and the incremental exclusivity from any pediatric study extension.

In practice, the seven-year ODE clock starts on the date of first FDA approval for the designated orphan use. If a sponsor receives approval for a second indication within the same rare disease during the ODE period, the exclusivity does not reset. If a competitor can demonstrate clinical superiority, the FDA can grant approval for the same drug for the same disease despite an active ODE, creating a residual litigation risk that standard IP models often underweight.

Case Study: Adalimumab and the Orphan Incentive Arbitrage
Adalimumab (AbbVie’s Humira) holds over ten FDA-approved indications. Four of these are for rare diseases and carry orphan designation. The remaining six, including rheumatoid arthritis, plaque psoriasis, and Crohn’s disease in non-orphan populations, account for the overwhelming majority of Humira’s $21 billion peak global sales. AbbVie captured orphan tax credits, user fee waivers, and priority review benefits for the rare-disease indications while those same indications contributed a small fraction of total revenue.

This is the structural critique at the center of the ODA reform debate. The incentives were meant to pull investment toward commercially unviable rare diseases. In cases like adalimumab, they also subsidized development for indications that would have been commercially attractive without any public support. Critics call this outcome ‘orphan washing.’ Industry advocates counter that the clinical data gathered for the orphan indications benefits all patients, regardless of which indication drives revenue.

The analytical point for IP teams is this: orphan designation on any indication attached to a high-revenue asset creates ODE value that is almost entirely independent of the clinical or commercial importance of that indication. Tracking designation status and ODE timelines across all indications of a given molecule is not optional for competitive intelligence work in this space.

Investment Strategy: ODE as a Moat Metric
Portfolio managers evaluating rare disease biotech assets should apply a framework that weights ODE independently from the patent estate. A company with a molecule whose base patents expire in year three of ODE coverage carries a meaningfully different risk profile from one where ODE and base patents co-terminate. The ‘ODE Moat Gap,’ defined as the years of ODE remaining after last patent expiry, is a useful single-metric screen for pricing power durability.

For assets in the ODE window with no blocking patents, the primary risk shifts from litigation to the clinical superiority challenge threshold. Understanding that threshold requires reading the original designation letter, the approved label, and any subsequent FDA correspondence on the indication scope. DrugPatentWatch provides direct access to this documentation layer across its global database.

5. How the ODA Created ‘Blockbuster’ Rare Disease Markets

The Numbers
From ODA enactment through December 2022, the FDA’s OOPD granted 6,340 orphan drug designations, producing 882 initial approvals covering 392 rare diseases. Orphan products now represent roughly one-third of all FDA-approved drugs and biologics by count, and 52% of 2024 CDER NME approvals. By 2017, all orphan products combined generated approximately $125 billion in global prescription sales, representing 16% of the total worldwide prescription market. Projections place orphan drugs at 25% of worldwide prescription sales within the next five years.

The economic concentration is striking. The mean annual cost per patient for an orphan drug was estimated at $150,854 in 2018, versus $33,654 for a non-orphan drug, a 4.5x differential. For ultra-rare conditions with fewer than 10,000 U.S. patients, annual per-patient costs routinely exceed $200,000.

Why the ‘No Reasonable Expectation of Profit’ Premise Collapsed
The ODA’s original legal standard for designation required that a sponsor demonstrate ‘no reasonable expectation of recovering costs of developing and making available’ the drug. This standard was calibrated for an era when no one anticipated gene therapies with market sizes of a few thousand patients but price tags above $1 million per dose.

Multiple studies now document that publicly listed pharmaceutical companies holding orphan drug market authorizations have higher market valuations and greater profitability than comparably sized companies without orphan portfolios. The gross margin differential, orphan rare disease industry above 80% versus pharmaceutical average of 16%, makes the ‘no reasonable expectation of profit’ justification implausible for most current orphan drug franchises.

This is not an argument against the ODA as such. It is an argument that the incentive calibration has not been updated in 40 years while the market it created has grown to $125 billion annually. That mismatch is where the reform pressure concentrates.

Key Takeaways: Section 5

Orphan drugs are now 52% of CDER NME approvals and are projected to reach 25% of global prescription sales, making rare disease IP the most strategically valuable category in pharma.
The mean 4.5x per-patient cost premium for orphan drugs over non-orphan drugs generates margins that directly contradict the original ODA premise of commercial non-viability.
The ‘blockbuster orphan’ phenomenon is not a market failure in isolation. It reflects a 40-year mismatch between static incentive calibration and a market that grew far beyond the ODA’s design parameters.

6. The ‘Salami-Slicing’ Problem: Evergreening Tactics in Orphan Drug Development
The Core Mechanics
Evergreening in the orphan drug context refers to repurposing an existing, often off-patent, molecule for a new rare disease indication to obtain a fresh seven-year ODE window, a new set of tax credits, and user fee waivers on what is commercially a mature product. The drug itself may require no new formulation work. The sponsor runs a small clinical trial, often in a patient population where placebo-controlled design is ethically or practically impossible, and files for orphan designation.

‘Salami slicing’ is a distinct but related tactic: artificially subdividing a patient population by genetic subtype, disease stage, or patient age to obtain multiple orphan designations for what is functionally the same indication. Each slice receives its own seven-year ODE. A sponsor who splits a disease into three designated subpopulations can theoretically accumulate overlapping exclusivity periods that extend effective market protection well beyond what any single patent or single ODE would provide.

The 2021 HHS OIG Report and Its Implications
A 2021 study by the Department of Health and Human Services Office of the Inspector General found that half of the 40 therapies with the highest combined Medicare Part B and Part D expenditures were orphan drugs, and a significant portion of those high-expenditure orphan drugs also had major non-orphan indications. The report did not conclude fraud, but it documented a systematic pattern: the FDA’s orphan incentive program was generating fiscal benefit for drugs whose primary commercial engine was non-orphan use.

For IP teams and compliance departments, this report is a benchmark for the regulatory scrutiny environment. An asset with orphan designation on a minor indication and dominant non-orphan revenue should be stress-tested for designation validity and tax credit defensibility. The relevant case law is developing rapidly.

The Catalyst v. Becerra Decision: Exclusivity Scope Under Fire
In 2021, the Eleventh Circuit decided Catalyst Pharmaceuticals Inc. v. Becerra, rejecting the FDA’s longstanding interpretation that ODE protects only the specific approved indication rather than the entire rare disease designated at the time of application. If the Catalyst interpretation were adopted broadly, a sponsor who obtained orphan designation for ‘Lambert-Eaton myasthenic syndrome’ and won approval for a specific symptom subset would hold exclusivity over the entire designated disease, blocking any competitor drug for the full seven-year window even if the competitor’s approved indication was clinically distinct.

The FDA stated its intent to continue tying exclusivity to approved uses rather than original designations. Congressional clarification through legislation has been discussed but not enacted as of April 2026. The doctrinal uncertainty persists.

For sponsors with active ODE positions, the Catalyst decision creates an argument for broader exclusivity scope that can be deployed against competitors seeking approval for related but clinically distinct indications within the same designated disease. For competitors and generic manufacturers, the same decision creates litigation exposure. Both sides need real-time tracking of the relevant case law and FDA guidance.

Investment Strategy Note: Assets in therapeutic areas where salami-slicing is prevalent (lysosomal storage disorders, metabolic enzyme deficiencies, neuromuscular conditions) carry higher regulatory risk than their current ODE positions suggest. Model a 15 to 25% probability haircut on projected exclusivity duration for assets in crowded designated disease categories.

7. Mark Cuban Cost Plus Drug Company: Business Model Anatomy

The Pricing Formula
MCCPDC’s published pricing formula is: acquisition cost plus 15% markup, plus a flat $5 pharmacy service fee, plus a $5 shipping fee. Every input is disclosed. The company posts acquisition costs publicly.

The transparency is the product. MCCPDC is not primarily competing on cost. It is competing on information. By making the acquisition cost visible, it exposes the spread between what drugs cost to source and what patients pay at traditional pharmacies using PBM-negotiated formularies. That exposure is uncomfortable for PBMs because the spread in generic drugs is often several hundred percent rather than the few percent that consumers assume.

Imatinib, the chronic myeloid leukemia generic, costs $34.50 for a 30-day supply through MCCPDC. The same drug through PBM-negotiated channels has been billed at $2,000 to $6,000 per month. Both prices reflect the ‘market price’ in their respective distribution channels. The difference is entirely a function of opacity and intermediary economics.

<clip>

And so on. I highly recommend the full read to better understand what the State of Michigan might do to help rare disease treatment - and just as importantly, what it should not do.